Trials / Unknown
UnknownNCT06200766
A Multicenter, Randomized, Double-blind, Three-arm, Parallel Clinical Endpoint Bioequivalence Study of Monometasone Furoate Nasal Spray in Patients With Seasonal Allergic Rhinitis
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 640 (estimated)
- Sponsor
- Zheng Liu ENT · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Taking the mamsonic acid nasal spray held by Zhejiang Xianxian Pharmaceutical Technology Co., Ltd. as the test agent,Bannicate nose spray (product name: inside: insideSchuro®) is a reference preparation. Among the seasonal allergic rhinitis patients, through comparative clinical end, evaluation.The biological equivalent of the two types of branic acid Miimone pine nose spray agent. Observe the test agent and reference preparation in the season.Safety in patients with sexual allergic rhinitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mometasone furoate as a nasal spray | Subjects received 2 presses in each side nostrils at the same time point (± 1h). |
Timeline
- Start date
- 2023-08-25
- Primary completion
- 2024-04-30
- Completion
- 2024-06-30
- First posted
- 2024-01-11
- Last updated
- 2024-01-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06200766. Inclusion in this directory is not an endorsement.